Sunshine Biopharma, Inc.
Sunshine Biopharma, Inc.
Your view on SBFMW
Overview
What the company does, where it operates, and who runs it.
About Sunshine Biopharma, Inc.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Steve N. Slilaty
- Headquarters
- 333 Las Olas Way, Fort Lauderdale, FL, US
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Steve N. Slilaty
- Headquarters
- 333 Las Olas Way, Fort Lauderdale, FL, US
Sunshine Biopharma, Inc. operates as a pharmaceutical and nutritional supplement company primarily dedicated to the research and development of innovative anticancer drugs. The company's pipeline includes Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin.
This compound is currently in development to address a broad spectrum of cancers, such as leukemia, lymphoma, and tumors affecting the testicular, lung, brain, prostate, bladder, colon, ovarian, and liver.
Significantly, Adva-27a has also shown effectiveness against multidrug-resistant cancer cells, including those associated with pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma. Another key therapeutic in development is SBFM-PL4, an anti-coronavirus treatment compound.
In addition to its pharmaceutical endeavors, Sunshine Biopharma offers a range of nutritional supplements, including the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, and continues to develop and market other scientifically-formulated nutritional products.
The company has forged a licensing agreement with the University of Georgia to further the development of its lead anti-coronavirus compound, SBFM-PL4. Sunshine Biopharma, Inc. is based in Pointe-Claire, Canada.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Sunshine Biopharma, Inc., and the rating behind it. SBFMW last traded at $0.04; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Sunshine Biopharma, Inc.. Starting points for Sunshine Biopharma, Inc.: EPS -$4.27, beta 1.31 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Sunshine Biopharma, Inc.. Sunshine Biopharma, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Sunshine Biopharma, Inc.. Trailing twelve-month EPS for Sunshine Biopharma, Inc. stands at -$4.27. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Sunshine Biopharma, Inc.. Sunshine Biopharma, Inc. has reported as a listed company since 2022. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Sunshine Biopharma, Inc. valued side by side against its closest peers. Sunshine Biopharma, Inc. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Sunshine Biopharma, Inc., and how their positions are changing. At a $195,226 market value, institutional positions materially move Sunshine Biopharma, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Sunshine Biopharma, Inc. executives and directors. Shares of Sunshine Biopharma, Inc. have traded between $0.04 and $0.24 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Sunshine Biopharma, Inc.. Sunshine Biopharma, Inc. is a $195,226 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Sunshine Biopharma, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Sunshine Biopharma, Inc.. Coverage tracks Sunshine Biopharma, Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.